Tecentriq

Roche nixes Tecentriq trial in early breast cancer, but it's 'still in the game' in key lung cancer use: exec
Roche nixes Tecentriq trial in early breast cancer, but it's 'still in the game' in key lung cancer use: exec
Fierce Pharma
Roche
Tecentriq
breast cancer
Teresa Graham
Pharma CEOs
Flag link:
Genentech reveals positive results from cancer combo therapy trial
Genentech reveals positive results from cancer combo therapy trial
Clinical Trials Arena
Genentech
Tecentriq
Avastin
liver cancer
hepatocellular carcinoma
Flag link:
Roche, Exelixis Suffer Another Late-Stage Cancer Combo Failure
Roche, Exelixis Suffer Another Late-Stage Cancer Combo Failure
BioSpace
Roche
Exelixis
renal cell carcinoma
Tecentriq
Cabometyx
clinical trials
Flag link:
Immuno-oncology goes subcutaneous
Immuno-oncology goes subcutaneous
EP Vantage
immuno-oncology
oncology
subcutaneous drug delivery
Keytruda
Merck
Tecentriq
Roche
Flag link:
Roche’s Tecentriq to be filed for early-stage liver cancer
Roche’s Tecentriq to be filed for early-stage liver cancer
Pharmaphorum
Roche
Tecentriq
Avastin
clinical trials
liver cancer
Flag link:
Roche wins earlier-than-expected approval for blockbuster Tecentriq in rare soft tissue cancer
Roche wins earlier-than-expected approval for blockbuster Tecentriq in rare soft tissue cancer
Endpoints
Roche
Tecentriq
FDA
soft tissue cancer
Flag link:
Combo of Roche's Tecentriq and Exelixis' Cabometyx fails another trial, this time in lung cancer
Combo of Roche's Tecentriq and Exelixis' Cabometyx fails another trial, this time in lung cancer
Fierce Pharma
Roche
Tecentriq
Exelixis
Cabometyx
clinical trials
non small cell lung cancer
Flag link:
Exelixis drug fails PhIII lung cancer trial with Cabometyx and Tecentriq combo
Exelixis drug fails PhIII lung cancer trial with Cabometyx and Tecentriq combo
Endpoints
Exelixis
Cabometyx
Tecentriq
metastatic non-small cell lung cancer
clinical trials
Flag link:
Roche, having shared data with regulators, unwraps results of subcutaneous Tecentriq phase 3 trial
Roche, having shared data with regulators, unwraps results of subcutaneous Tecentriq phase 3 trial
Fierce Pharma
Roche
Tecentriq
clinical trials
non-small cell lung cancer
Flag link:
Roche Withdraws Tecentric for Bladder Cancer Indication
Roche Withdraws Tecentric for Bladder Cancer Indication
BioSpace
Roche
Genentech
bladder cancer
metastatic bladder cancer
Tecentriq
Flag link:
Racing Merck and Pfizer, Roche readies to file subcutaneous Tecentriq after posting phase 3 data
Racing Merck and Pfizer, Roche readies to file subcutaneous Tecentriq after posting phase 3 data
Fierce Pharma
Roche
Pfizer
Merck
Tecentriq
clinical trials
cancer
checkpoint inhibitors
Flag link:
Roche Sees More Growth Opportunities for Phesgo, Tecentriq; Still Optimistic on Tiragolumab
Roche Sees More Growth Opportunities for Phesgo, Tecentriq; Still Optimistic on Tiragolumab
Precision Oncology News
Roche
earnings
oncology
Phesgo
Tecentriq
Flag link:
Merck fights back against Roche in adjuvant lung cancer therapy
Merck fights back against Roche in adjuvant lung cancer therapy
Pharmaforum
Merck
Keytruda
non-small cell lung cancer
clinical trials
Roche
Tecentriq
Flag link:
Chasing Roche, Merck unveils adjuvant lung cancer data for Keytruda
Chasing Roche, Merck unveils adjuvant lung cancer data for Keytruda
Pharmaforum
Merck
Roche
Keytruda
clinical trials
non-small cell lung cancer
Tecentriq
Flag link:
Roche builds case for TIGIT combo in untreated lung cancer
Roche builds case for TIGIT combo in untreated lung cancer
Pharmaforum
Roche
anti-TIGIT
tiragolumab
Tecentriq
lung cancer
Flag link:
Roche scores adjuvant lung cancer approval for Tecentriq
Roche scores adjuvant lung cancer approval for Tecentriq
Pharmaforum
Roche
Tecentriq
FDA
non-small cell lung cancer
Flag link:
Roche's Tecentriq crosses the finish line first in adjuvant lung cancer, potentially kicking off gold rush
Roche's Tecentriq crosses the finish line first in adjuvant lung cancer, potentially kicking off gold rush
Endpoints
Roche
Tecentriq
non-small cell lung cancer
FDA
Flag link:
ESMO: Exelixis lays out promising early Cabometyx combo data in prostate cancer, but key discrepancies persist
ESMO: Exelixis lays out promising early Cabometyx combo data in prostate cancer, but key discrepancies persist
Fierce Pharma
ESMO
Exelixis
Cabometyx
Roche
Tecentriq
clinical trials
prostate cancer
Flag link:
Roche to withdraw US accelerated approval for Tecentriq to treat breast cancer
Roche to withdraw US accelerated approval for Tecentriq to treat breast cancer
Pharmaceutical Business Review
Roche
Tecentriq
Abraxane
triple negative breast cancer
FDA
accelerated approval
Flag link:
Roche pulls Tecentriq breast cancer nod after post-approval trial flop
Roche pulls Tecentriq breast cancer nod after post-approval trial flop
Fierce Pharma
Roche
Tecentriq
breast cancer
triple negative breast cancer
postmarketing studies
Flag link:

Pages